Veligrotug - Viridian Therapeutics
Alternative Names: Anti-IGF1R monoclonal antibody - Viridian Therapeutics; AVE 1642; VRDN 001; ZB 001; ZL-1108Latest Information Update: 02 Jun 2025
At a glance
- Originator ImmunoGen
- Developer sanofi-aventis; Viridian Therapeutics; ZAI Lab; Zenas BioPharma
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action IGF type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Graves ophthalmopathy
- Discontinued Breast cancer; Multiple myeloma; Solid tumours
Most Recent Events
- 20 May 2025 Efficacy and adverse events data from phase-III (phase-I/II/III) trial in Graves Ophthalmopathy released byViridian Therapeutics
- 07 May 2025 Veligrotug - Viridian Therapeutics receives Breakthrough Therapy status for Graves ophthalmopathy in USA
- 19 Mar 2025 Viridian Therapeutics announces intention to submit MAA to EMA for Graves ophthalmopathy in the first half of 2026